Targeted anti-vascular therapies for ovarian cancer: Current evidence

M. Hall, C. Gourley, I. Mcneish, J. Ledermann, M. Gore, G. Jayson, T. Perren, G. Rustin, S. Kaye

    Research output: Contribution to journalArticlepeer-review


    Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer - angiogenesis. © 2013 Cancer Research UK. All rights reserved.
    Original languageEnglish
    Pages (from-to)250-258
    Number of pages8
    JournalBritish Journal of Cancer
    Issue number2
    Publication statusPublished - Feb 2013


    • Anti-angiogenesis
    • Metronomic chemotherapy
    • Ovary cancer
    • Tyrosine kinase inhibitors
    • Vascular disruptive agents
    • VEGF inhibitors


    Dive into the research topics of 'Targeted anti-vascular therapies for ovarian cancer: Current evidence'. Together they form a unique fingerprint.

    Cite this